// App-Quantinova.ai

2672 : In Vivo Efficacy of PI3K Pathway Signaling Inhibition for Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Sarah K Tasian

Principal Investigators

  • Yong Li

  • Theresa Ryan

  • Tiffaney Vincent

  • David T. Teachey

  • Mignon L. Loh

  • Stephen P. Hunger

  • Martin P. Carroll

  • Stephan A. Grupp

Medical Centers

  • Division of Hematology/Oncology, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • Pediatric Hematology/Oncology/BMT, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO

  • Department of Pathology, The Children's Hospital of Philadelphia, Philadelphia, PA

  • Department of Pathology, The Children's Hospital of Philadelphia, Philadelphia, PA

  • Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA

  • Neonatology, Benioff Childrens Hospital, University of California San Francisco, San Francisco, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Hematological malignancies

Biomarkers

  • Breakpoint Cluster Region

  • Ph chromosome

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Phosphorylated-extracellular signal regulated kinase

  • Janus kinase

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • Idelalisib

  • Rapacan

  • AZD-2014

  • Alpelisib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved